SciFiMed will help patients suffering from

 

- impaired defence against infections,

- incurable renal,

- autoimmune or 

- eye diseases.

 

All these diseases share an association with dysregulation of the complement system, which is a major component of the immune system.

Complement factor H (FH) and FH-related (FHR) proteins are components of the complement system that are strongly associated with systemic and organ-specific complement-mediated pathologies. In contrast to FH, the function of the remaining six highly homologous FHR proteins is mostly unknown and, hence, their role in the different disease-specific pathogenic mechanisms remain elusive.

Our EU consortium will unravel the mysteries of the FH-protein family’s contributions to diseases.

 

Then, via an ambitious and transdisciplinary fundamental science-to-technology transfer, a proof-of-principle for a multiplex detection system will be developed to simultaneously quantify and analyse the functional activity of all seven FH-protein family members in patient samples – on site, putting diagnostic technology directly into physicians’ hands.

 

In the future, this high-impact project propels immunological research in Europe, enables new product development of bioanalytical companies, modernizes the EU-diagnostic market and provides new perspectives for patient treatment, which in turn will pave the way for novel approaches for drug development.

Man jump through the gap between hill..j
"Everything is possible,
even the impossible"

Mary Poppins

This project has received funding from the European Union’s Horizon 2020

research and innovation programme under grant agreement No 899163

©2020 by SciFiMed.

  • Twitter
  • RESEARCH%20GATE_edited
  • LinkedIn